EyePoint (EYPT) Net Margin (2010 - 2026)
EyePoint (EYPT) posted Net Margin of 17270.26% for Q1 2026, down 58.37% sequentially from 10904.68% in Q4 2025, and down 1705591.0% YoY from N/an in Q1 2025.
EyePoint (EYPT) Net Margin (2010 - 2026) Analysis & Trends
EyePoint has reported Net Margin for 17 years, with the latest figure at 17270.26% in Q1 2026.
- Quarterly Net Margin fell 1705591.0% year-over-year to 17270.26% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4031.1% (down 375630.0% YoY) and the FY2025 annual result came in at 739.42%, down 43699.0% from the prior year.
- Net Margin retreated to 17270.26% in Q1 2026 per EYPT's latest filing, from 10904.68% in the prior quarter.
- Over five years, Net Margin peaked at 121.03% in Q4 2023 and troughed at 17270.26% in Q1 2026.
- A 5-year average of 2398.59% and a median of 384.7% in 2023 frame the typical range for Net Margin.
- The sharpest annual moves came in 2023 and 2026: Net Margin jumped 74030 bps in 2023, then sank 1705591 bps in 2026.
- Over 5 years, Net Margin stood at 420.54% in 2022, then surged by 71 bps to 121.03% in 2023, then tumbled by 195 bps to 357.26% in 2024, then plunged by 2952 bps to 10904.68% in 2025, then tumbled by 58 bps to 17270.26% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 17270.26%, 10904.68%, and 6183.44% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | -18,633.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18,633.14% |
| Mar 31, 2026 | -17,270.26% |
| Dec 31, 2025 | -10,904.68% |
| Sep 30, 2025 | -6,183.44% |
| Jun 30, 2025 | -1,114.31% |
| Mar 31, 2025 | -214.35% |
| Dec 31, 2024 | -357.26% |
| Sep 30, 2024 | -278.99% |
| Jun 30, 2024 | -325.27% |
| Mar 31, 2024 | -839.52% |
| Dec 31, 2023 | -121.03% |
| Sep 30, 2023 | -163.37% |
| Jun 30, 2023 | -384.70% |
| Mar 31, 2023 | -290.37% |
| Dec 31, 2022 | -420.54% |
| Sep 30, 2022 | -903.68% |
| Jun 30, 2022 | -794.17% |
| Mar 31, 2022 | -210.15% |
| Dec 31, 2021 | -172.59% |
| Sep 30, 2021 | -184.36% |